



2215 Yukon St .
Vancouver, BC
Canada, V5Y 0A1
T 1. 604.559.9005
abcellera.com

NEWS RELEASE

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

2025-01-21

VANCOUVER, British Columbia--(BUSINESS WIRE)-- **AbCellera** (Nasdaq: ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on **AbCellera's Investor Relations website**. A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit **www.abcellera.com**.

Inquiries

Media: Tiffany Chiu; **media@abcellera.com**, +1(236)521-6774

Partnering: Murray McCutcheon, Ph.D.; **partnering@abcellera.com**, +1(604)559-9005

Investor Relations: Peter Ahn; **ir@abcellera.com**, +1(778)729-9116

Source: AbCellera Biologics Inc.